* Settles suit over generic version of Treximet
* Says litigation against other defendants to continue
* Pozen shares up 2 pct
April 14 Pharmaceutical company Pozen Inc
POZN.O settled a suit over its Treximet migraine drug with
top generics maker Teva Pharmaceutical Industries Ltd
(TEVA.TA), opening the door to settlements with other
Teva Pharmaceuticals USA had filed with the U.S. Food and
Drug Administration, seeking marketing approval for a generic
version of Treximet. Treximet is marketed by Pozen's U.S.
licensee GlaxoSmithKline (GSK.L).
The settlement will conclude Pozen's litigation with Teva,
but does not end the ongoing litigation against the other three
defendants, Par Pharmaceutical Inc PRX.N, Alphapharm Pty Ltd,
and Dr. Reddys Laboratories Inc (REDY.BO), Pozen said in a
Teva will agree to be bound by the outcome of such
litigation or any resulting settlements with third parties,
Shares of Pozen were up nearly 2 percent at $10.44 in
morning trade Wednesday on Nasdaq.
(Reporting by Shailesh Kuber in Bangalore; Editing by Vinu